| Due Diligence for Asset Managers |
|---|
|
Analyze the public filings of asset managers Dive into the EDGAR, IAPD, CAFR source data |
|
⚲
|
| Keyboard |
| Repligen Corp | |
|---|---|
| Ticker | RGEN |
| CIK # | 0000730272 |
| CUSIP | 759916109 |
| Sector | Life Sciences - Biological Products, (No Disgnostic Substances) |
| Address | 41 Seyon Street Building 1, Suite 100, Waltham, MA 02453 |
| Source | [EDGAR] |
| Reg D Offering (Form D) | Filed | Raised | Terms |
|---|---|---|---|
| Repligen Corp | 2019-06-13 | 48.0 M | Exemption: 506(b) · Duration: One year or less · Revenue: Decline to Disclose |
| CIK | Filing | 2011 - 2026 |
|---|---|---|
| [0000730272] | 10-K | |
| [0000730272] | 10-Q | |
| [0000730272] | 3 | |
| [0000730272] | 4 | |
| [0000730272] | 5 | |
| [0000730272] | 8-K | |
| [0000730272] | D | |
| [0000730272] | SC 13G |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed | % Owned |
|---|---|---|---|
| FMR LLC | Repligen Corp | [2026-02-05] | 0.0 |
| BlackRock Inc | Repligen Corp | [2022-09-08] | 10.2 |
| Price T Rowe Associates Inc /MD/ | Repligen Corp | [2022-02-14] | 5.5 |
| TimesSquare Capital Management LLC | Repligen Corp | [2018-02-14] | 5.8 |
| Vanguard Group Inc | Repligen Corp | [2018-02-09] | 6.48 |
| Eddleman Roy T | Repligen Corp | [2017-08-21] | 11.0 |
| OppenheimerFunds Inc | Repligen Corp | [2016-02-04] | 5.67 |
| FMR LLC | Repligen Corp | [2015-02-13] | 0.0 |
| Invesco Ltd | Repligen Corp | [2015-02-11] | 5.3 |
| Northpointe Capital LLC | Repligen Corp | [2013-02-11] | 7.4 |
| BlackRock Inc | Repligen Corp | [2013-01-30] | 5.93 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Loeillot Olivier
Stock Option (Right to Buy) · derivative
|
2026-03-05 | Grant | 25,890 | $0.00 | |
|
Garland Jason K
Stock Option (Right to Buy) · derivative
|
2026-03-05 | Grant | 8,315 | $0.00 | |
|
Kuriyel RALF
Stock Option (Right to Buy) · derivative
|
2026-03-05 | Grant | 5,669 | $0.00 | |
|
Loeillot Olivier
Common Stock
|
2026-03-05 | Grant | 24,134 | $0.00 | |
|
Bylund James
Stock Option (Right to Buy) · derivative
|
2026-03-05 | Grant | 8,315 | $0.00 | |
|
Kuriyel RALF
Common Stock
|
2026-03-05 | Grant | 5,284 | $0.00 | |
|
Garland Jason K
Common Stock
|
2026-03-05 | Grant | 7,751 | $0.00 | |
|
Bylund James
Common Stock
|
2026-03-05 | Grant | 7,751 | $0.00 | |
|
Bylund James
Common Stock
|
2026-03-04 | Tax withheld | 62 | $125.84 | 7,802 |
|
Kuriyel RALF
Common Stock
|
2026-03-04 | Grant | 125 | $0.00 | |
|
Bylund James
Common Stock
|
2026-03-04 | Grant | 125 | $0.00 | |
|
Kuriyel RALF
Common Stock
|
2026-03-04 | Tax withheld | 42 | $125.84 | 5,285 |
|
Garland Jason K
Common Stock
|
2026-03-02 | Tax withheld | 715 | $124.97 | 89,354 |
|
Kuriyel RALF
Common Stock
|
2026-03-02 | Tax withheld | 923 | $124.97 | 115,347 |
|
Douglass Brian Robb
Common Stock
|
2026-03-02 | Tax withheld | 221 | $124.97 | 27,618 |
|
Hunt Anthony
Common Stock
|
2026-03-02 | Tax withheld | 9,897 | $124.97 | 1,236,828 |
|
Loeillot Olivier
Common Stock
|
2026-03-02 | Tax withheld | 1,610 | $124.97 | 201,202 |
|
Bylund James
Common Stock
|
2026-03-02 | Tax withheld | 2,433 | $124.97 | 304,052 |
|
Loeillot Olivier
Common Stock
|
2026-02-27 | Tax withheld | 344 | $128.73 | 44,283 |
|
Garland Jason K
Common Stock
|
2026-02-27 | Tax withheld | 327 | $128.73 | 42,095 |
| showing 20 of 200 most recent transactions | |||||
| 13F Ownership Over Time | Holders | Shares Held |
|---|---|---|
| 2026-03-31 | 443 | 59,099,162 |
| 2025-12-31 | 477 | 56,589,303 |
| 2025-09-30 | 454 | 55,805,930 |
| 2025-06-30 | 445 | 50,152,949 |
| 2025-03-31 | 442 | 48,832,248 |
| 2024-12-31 | 432 | 47,993,292 |
| 2024-09-30 | 447 | 48,462,420 |
| 2024-06-30 | 455 | 50,194,820 |
| 2024-03-31 | 493 | 53,988,437 |
| 2023-12-31 | 471 | 54,141,768 |
| 2023-09-30 | 439 | 52,092,702 |
| 2023-06-30 | 449 | 50,105,308 |